Document is current
Any future updates will be listed below
-
Authors
O’Donnell, Patricio
Dong, Cheng
Murthy, Venkatesha
Asgharnejad, Mahnaz
Du, Xiaoming https://orcid.org/0000-0001-7206-5282
Summerfelt, Ann
Lu, Hong
Xu, Lin
Wendland, Jens R.
Dunayevich, Eduardo
Buhl, Derek L.
Litman, Robert
Hetrick, William P.
Hong, L. Elliot
Rosen, Laura B.
- License Information
-
More Information
Article History
Received: 14 September 2022
Revised: 23 February 2023
Accepted: 24 February 2023
First Online: 16 March 2023
Competing interests
: POD and DLB were employed at Takeda Pharmaceuticals USA, Inc. throughout the conception and execution of the study and are currently employees and shareholders of Sage Therapeutics. CD, VM, MA, HL, LX, JRW, and LBR are employees of Takeda Pharmaceuticals USA, Inc., and shareholders of Takeda Pharmaceutical Company Limited. ED is an employee of Neurocrine Biosciences Inc. and was employed at Takeda when the study was initiated. LEH has received or plans to receive research funding or consulting fees from Heptares Therapuetics Ltd, Luye Pharma Group, Mitsubishi, Neuralstem Inc., Pfizer, Regeneron, Sound Pharma, Taisho Pharmaceutical, Takeda, and Your Energy Systems LLC. XD, AS, RL, and WPH have nothing to disclose.
